KRTX News and Press, Karuna Therapeutics Inc. From 06/03/20

Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that Steve Pau...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, announced today that data from the Phase 2...

Biotech Pulse Source: COVID-19 image by Getty Images; edits by PrudentBiotech.com It has taken a pandemic for biotechs to take flight towards their all-time high. One of the first industry groups to recover from the virus-related selloff and be neutral for the year, biotech indexes hav...

Karuna Therapeutics (NASDAQ: KRTX ): Q1 GAAP EPS of -$0.33 beats by $0.10 . More news on: Karuna Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

End of Phase 2 meeting scheduled with the U.S. Food and Drug Administration (FDA) with feedback from the meeting expected to be announced in the second quarter Additional data from Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia t...

Adverum Biotechnologies (NASDAQ: ADVM ) initiated with Buy rating and $17 (36% upside) price target at Goldman Sachs. More news on: Adverum Biotechnologies, Inc., Alector, Inc., Alexion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced the appointment of Christo...

Market Pulse The COVID-19 pandemic has thrust biopharma to the forefront in the search for a solution. And biotechs will remain at the investing forefront as the quest for anti-viral treatments and vaccines continues to be the race for the holy grail that can restore economic activity around...

Investment Thesis Karuna Therapeutics ( KRTX ) was the most successful IPO in the US in 2019 in terms of percentage share price gain delivering a 420% overall gain after joining in July in an IPO priced at $16. Karuna 1-year share price performance. Source: TradingView . The catalyst...

The most important thing is to survive the outbreak. Thereafter, for our portfolio to survive too so it can do well when the situation is favorable. Market Pulse The stock market remains unsettled and vulnerable to sharp declines. Over the last two weeks, the market has forcefully steppe...